Acceleron Pharma Release: ACE-011 Phase 1 Results Published in the Journal of Bone and Mineral Research

CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells and Celgene Corporation, today announced the publication of the ACE-011 Phase 1 clinical study demonstrating that ACE-011 increased biomarkers of bone formation, decreased biomarkers of bone resorption and increased hemoglobin levels in postmenopausal women. The paper was published online in the Journal of Bone and Mineral Research (JBMR) and is titled “A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women.”